Live

achondroplasia

2 articles

BridgeBio Surges on Rare-Disease Momentum as Analyst Sees $93 Upside

Benzinga

Benzinga·Mar 10·Vandana Singh

BridgeBio Surges on Rare-Disease Momentum as Analyst Sees $93 Upside

BridgeBio Pharma jumps 12.6% after William Blair initiates coverage with Outperform rating, citing accelerating product launches and robust rare-disease pipeline.

PFEBBIOBMRNALNYregulatory approvaldrug development

Skeletal Dysplasia Market Set to Surge 54% to $5.37B by 2032

GlobeNewswire Inc.

GlobeNewswire Inc.·Mar 5·Researchandmarkets.Com

Skeletal Dysplasia Market Set to Surge 54% to $5.37B by 2032

Global skeletal dysplasia market projected to grow from $3.48B (2026) to $5.37B (2032) at 7.42% CAGR, driven by diagnostic advances and innovative therapies.

PFENVSRAREREGNBMRNrare diseasebiologic therapy